🏅 FDA Orphan Designation

Exosurf Neonatal for Intratracheal Suspension

Colfosceril palmitate, cetyl alcohol, tyloxapol

Manufacturer: Glaxo Wellcome Inc.

Indicated for:

Neonatal acute respiratory distress syndrome

FDA-Approved Indications (1)

Neonatal acute respiratory distress syndrome

Prevention of hyaline membrane disease (HMD) in infants born at 32 weeks gestation or less

Population: infants born at 32 weeks gestation or less

Indications & Usage

Prevention of hyaline membrane disease (HMD), also known as respiratory distress syndrome (RDS), in infants born at 32 weeks gestation or less and in the treatment of established HMO at all gestational ages

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.